Yuanjie Niu

Also affiliated with Second Hospital of Tianjin Medical University, Tianjin Medical University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer”.

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

Cell Death and Disease(2020)10.1038/s41419-020-02970-4

N/A

0DataRank · unranked

14 citations

Chang-Yi Lin, Hao Tian, Wan-Ying Lin, Bosen You, Jieyang Lu +7 more

The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer

Cell Death and Disease(2020)10.1038/s41419-020-02932-w

N/A

0DataRank · unranked

35 citations

Yin Sun, Min Tang, Chao Liang, Chi‐Ping Huang, Yuanjie Niu +3 more